Nancy-Ellen Haynes

USPTO Granted Patents = 25 (Patent Applications = 3)

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 6.7

ph-index = 10

Forward Citations = 348(Granted Patents)

Location History:

Cranford, NJ (US) (2001 - 2014)
Granford, NJ (US) (2016)

Company Filing History:

24 out of 4,945

Hoffmann-la Roche Inc.

1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2016

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE46024 - Thyroid hormone analogs (2016-06-06),

2. 8722661 - Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase (2014-05-13),

3. 8501732 - Aminomethyl quinolone compounds (2013-08-06),

4. 8471027 - Adamantyl compounds (2013-06-25),

5. 8258134 - Pyridazinone glucokinase activators (2012-09-04),

6. 8222416 - Azaindole glucokinase activators (2012-07-17),

7. 8076334 - Prodrugs of thyroid hormone analogs (2011-12-13),

8. 7741327 - Pyrrolidinone glucokinase activators (2010-06-22),

9. 7728029 - Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase (2010-06-01),

10. 7622492 - Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase (2009-11-24),

11. 7452882 - Thyroid hormone analogs (2008-11-18),

12. 7259166 - Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators (2007-08-21),

13. 7223868 - Heteroaromatic glucokinase activators (2007-05-29),

14. 7132425 - 5-substituted-six-membered heteroaromatic glucokinase activators (2006-11-07),

15. 7105671 - Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators (2006-09-12),

Title: The Innovative Journey of Nancy-Ellen Haynes in Pharmaceutical Patenting

Introduction: Nancy-Ellen Haynes, a prominent inventor based in Cranford, NJ, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 25 patents, her innovative work primarily focuses on compounds and therapies aimed at treating various medical conditions, showcasing her commitment to advancing healthcare solutions.

Latest Patents: Among her latest patents, Nancy-Ellen Haynes has developed thyroid hormone analogs that consist of specific compounds and pharmaceutically acceptable salts. These innovations are targeted towards the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes, and related disorders. Furthermore, these compounds show promise for treating conditions like non-alcoholic steatohepatitis (NASH), atherosclerosis, cardiovascular diseases, hypothyroidism, and thyroid cancer.

Another significant patent involves pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase. The compounds described in this patent also demonstrate anticancer activity, highlighting her pivotal role in discovering potential treatments for complex diseases.

Career Highlights: Throughout her career, Nancy-Ellen Haynes has held positions at prestigious companies, including Hoffmann-La Roche Inc., where she has applied her innovative mind to develop therapeutic solutions. Her extensive work and commitment to research have earned her a respected place in the pharmaceutical industry.

Collaborations: Nancy-Ellen has collaborated with influential figures in the field, such as Ramakanth Sarabu and Robert Francis Kester. These partnerships have fostered an environment of innovation, leading to groundbreaking advancements in the pharmaceutical landscape.

Conclusion: Nancy-Ellen Haynes stands as a beacon of innovation within the pharmaceutical industry. Her impressive array of patents and collaborative endeavors demonstrates her unwavering dedication to improving health outcomes through inventive therapeutic solutions. The impact of her work is felt across various medical fields, making her a notable figure in the realm of patenting and innovation.

This text is generated by artificial intelligence and may not be accurate.